Infectious Disease Diagnostics Testing Market Growth Outlook Through 2024-2033

Infectious disease diagnostics testing refers to the process of identifying the presence of pathogens, such as bacteria, viruses, fungi, or parasites, in a patient’s body. These tests are crucial for diagnosing infectious diseases and guiding appropriate treatment decisions. Infectious disease diagnostics testing plays a vital role in controlling the spread of infectious diseases, guiding treatment decisions, and monitoring outbreaks.

Sizing and Forecast

The infectious disease diagnostics testing market size has grown strongly in recent years. It will grow from $35.09 billion in 2023 to $38.52 billion in 2024 at a compound annual growth rate (CAGR) of 9.8%. The growth in the historic period can be attributed to rising disease outbreaks such as SARS, Ebola, and Zika, growing awareness among healthcare professionals and the general public about the importance of early detection and prevention of infectious diseases, rise in government-funded programs for disease surveillance, control, and prevention, increasing global travel and trade have facilitated the spread of infectious diseases, and increased healthcare spending, particularly in emerging economies.

The infectious disease diagnostics testing market size is expected to see rapid growth in the next few years. It will grow to $58.84 billion in 2028 at a compound annual growth rate (CAGR) of 10.2%. The growth in the forecast period can be attributed to the continuous emergence of novel pathogens, such as new strains of influenza or coronaviruses, the shift towards personalized medicine and targeted therapies, increasing demand for rapid and on-site testing solutions, Growing emphasis on epidemiological surveillance and early detection systems, and increased research and developments activities focused on developing novel diagnostic technologies and biomarkers. Major trends in the forecast period include miniaturization and portability of diagnostic devices, adoption of multiplex assays capable of detecting multiple pathogens simultaneously, integration of digital health solutions, such as mobile apps and telemedicine platforms, adoption of next-generation sequencing (NGS) technologies in infectious disease diagnostics, advancements in biosensor technologies for rapid and sensitive detection of infectious agents, and integration of AI and machine learning algorithms into diagnostic platforms

Order your report now for swift delivery, visit the link:
https://www.thebusinessresearchcompany.com/report/infectious-disease-diagnostics-testing-global-market-report

Segmentation & Regional Insights

The infectious disease diagnostics testing market covered in this report is segmented –

1) By Type: Molecular Diagnostic Test, Point Of Care Tests (POCT) Infectious Disease Diagnostics Test
2) By Application: Respiratory, Human Immunodeficiency Virus (HIV), Healthcare-Associated Infections (HAIs), Sexual Health, Tropical Diseases, Liver
3) By End-User: Diagnostic Laboratories, Hospitals And Clinics, Academic Research Institutes, Other End-Users

North America was the largest region in the infectious disease diagnostics testing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the infectious disease diagnostics testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Intrigued to explore the contents? Secure your hands-on a free sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15831&type=smp

Major Driver Impacting Market Growth

A rise in respiratory infections is expected to propel the growth of the infectious disease diagnostic testing market going forward. Respiratory infections affect the respiratory system, including the nose, throat, airways, and lungs. The increasing respiratory infections are due to viral and bacterial transmission through close contact with infected individuals, poor hygiene practices, crowded living conditions, and seasonal variations in weather patterns. Infectious disease diagnostic testing is essential for diagnosing and treating respiratory infections as it can precisely identify pathogens such as bacteria and viruses in patient samples. For instance, in February 2024, according to the Canadian Institute for Health Information, a Canada-based non-profit organization, hospitalizations for acute upper respiratory infections increased by 32% from 2,114 in 2022 to 2,797 cases in 2023. Therefore, the rise in respiratory infections is driving the infectious disease diagnostic testing market.

Key Industry Players

Major companies operating in the infectious disease diagnostics testing market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Becton Dickinson And Company, Quest Diagnostics Incorporated, Grifols S.A., Hologic Inc., PerkinElmer Inc., bioMérieux SA, Quidel Corporation, Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., DiaSorin SpA (Luminex), Myriad Genetics Inc., Seegene Inc., Ortho Clinical Diagnostics Inc., OraSure Technologies Inc., Meridian Bioscience Inc., Trinity Biotech PLC, Biodesix Inc., Helix OpCo LLC, Inovio Pharmaceuticals Inc.

The infectious disease diagnostics testing market report table of contents includes:

1. Executive Summary
2. Infectious Disease Diagnostics Testing Market Characteristics
3. Infectious Disease Diagnostics Testing Market Trends And Strategies
4. Infectious Disease Diagnostics Testing Market – Macro Economic Scenario
5. Global Infectious Disease Diagnostics Testing Market Size and Growth
.
.
.
32. Global Infectious Disease Diagnostics Testing Market Competitive Benchmarking
33. Global Infectious Disease Diagnostics Testing Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Infectious Disease Diagnostics Testing Market
35. Infectious Disease Diagnostics Testing Market Future Outlook and Potential Analysis
36. Appendix